Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker PTGX
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Oct 27, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | BlackRock, Inc. | 9.83M | 15.2% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | Mark C. Wehrly | 6.43M | 10.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | John R. Warren | 6.43M | 10.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | Andrew J. M. Spokes | 6.43M | 10.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | Daniel S. Short | 6.43M | 10.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | Edric C. Saito | 6.43M | 10.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | Roberts, Jr., Thomas G. | 6.43M | 10.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | Luo Patrick (Cheng) | 6.43M | 10.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | Michael G. Linn | 6.43M | 10.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | David T. Kim | 6.43M | 10.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | Avner A. Husen | 6.43M | 10.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | Nicolas Giauque | 6.43M | 10.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | Varun N. Gehani | 6.43M | 10.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | Hannah E. Dunn | 6.43M | 10.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | Philip D. Dreyfuss | 6.43M | 10.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | Joshua J. Dapice | 6.43M | 10.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | Farallon Healthcare Partners (GP), L.L.C. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | Farallon F5 (GP), L.L.C. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | Farallon Institutional (GP) V, L.L.C. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | Farallon Partners, L.L.C. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | Farallon Healthcare Partners Master, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | Farallon Capital F5 Master I, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | Farallon Capital (AM) Investors, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | Farallon Capital Offshore Investors II, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | Four Crossings Institutional Partners V, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | Farallon Capital Institutional Partners III, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | Farallon Capital Institutional Partners II, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | Farallon Capital Institutional Partners, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | Farallon Capital Partners, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | Farallon Capital Management, L.L.C. | 6.43M | 10.0% | SCHEDULE 13G/A ↗ |
| Aug 7, 2026 | SCHEDULE 13G | PTGX Protagonist Therapeutics, Inc. | State Street Corporation | 3.32M | 5.2% | SCHEDULE 13G ↗ |
| May 12, 2026 | SCHEDULE 13G | PTGX Protagonist Therapeutics, Inc. | State Street Corporation | 3.12M | 4.9% | SCHEDULE 13G ↗ |
| Apr 30, 2026 | SCHEDULE 13G | PTGX Protagonist Therapeutics, Inc. | Vanguard Capital Management | 3.25M | 5.1% | SCHEDULE 13G ↗ |
| Apr 29, 2026 | SCHEDULE 13G | PTGX Protagonist Therapeutics, Inc. | Vanguard Portfolio Management | 3.53M | 5.5% | SCHEDULE 13G ↗ |
| Mar 27, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | The Vanguard Group | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | Roderick Wong | 5.06M | 8.1% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | RTW Investments, LP | 5.06M | 8.1% | SCHEDULE 13G/A ↗ |
| Feb 10, 2026 | SCHEDULE 13G | PTGX Protagonist Therapeutics, Inc. | Wellington Investment Advisors Holdings LLP | 3.17M | 5.1% | SCHEDULE 13G ↗ |
| Feb 10, 2026 | SCHEDULE 13G | PTGX Protagonist Therapeutics, Inc. | Wellington Group Holdings LLP | 3.17M | 5.1% | SCHEDULE 13G ↗ |
| Feb 10, 2026 | SCHEDULE 13G | PTGX Protagonist Therapeutics, Inc. | Wellington Management Group LLP | 3.17M | 5.1% | SCHEDULE 13G ↗ |
| Feb 6, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | Mark C. Wehrly | 6.25M | 10.0% | SCHEDULE 13G/A ↗ |
| Feb 6, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | John R. Warren | 6.25M | 10.0% | SCHEDULE 13G/A ↗ |
| Feb 6, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | Andrew J. M. Spokes | 6.25M | 10.0% | SCHEDULE 13G/A ↗ |
| Feb 6, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | Daniel S. Short | 6.25M | 10.0% | SCHEDULE 13G/A ↗ |
| Feb 6, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | William Seybold | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 6, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | Edric C. Saito | 6.25M | 10.0% | SCHEDULE 13G/A ↗ |
| Feb 6, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | Roberts, Jr., Thomas G. | 6.25M | 10.0% | SCHEDULE 13G/A ↗ |
| Feb 6, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | Rajiv A. Patel | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 6, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | Luo Patrick (Cheng) | 6.25M | 10.0% | SCHEDULE 13G/A ↗ |
| Feb 6, 2026 | SCHEDULE 13G/A (amended) | PTGX Protagonist Therapeutics, Inc. | Michael G. Linn | 6.25M | 10.0% | SCHEDULE 13G/A ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 8:02 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances